Erlotinib has shown efficacy for second- or third-line treatment of NSCLC [1], as maintenance therapy [2] and for the first-line treatment of EGFR mutation-positive disease [3,4]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.